The LASSO Program in Oslo: Harm reduction using buprenorphine-naloxone (Suboxone®) in a low threshold setting
Kaydedildi:
Henriksen, K., et al., The LASSO Program in Oslo: Harm reduction using buprenorphine-naloxone (Suboxone®) in a low threshold setting. European Addiction Research, vol. 24, n. 6, 2018, p. 286-292.
Ref.
548068
Yer:
SIIS R.1142
Palabras clave:
Drogodependencias, Reducción de daños, Tratamiento, Programas de mantenimiento, Buprenorfina, Programas de bajo umbral, Evaluación de servicios, Experiencias, Noruega
Drogodependencias, Reducción de daños, Tratamiento, Programas de mantenimiento, Buprenorfina, Programas de bajo umbral, Evaluación de servicios, Experiencias, Noruega
Benzer Materyaller: The LASSO Program in Oslo: Harm reduction using buprenorphine-naloxone (Suboxone®) in a low threshold setting
- A PILOT STUDY OF BUPRENORPHINE-NALOXONE COMBINATION TABLET (SUBOXONE) IN TREATMENT OF OPIOID DEPENDENCE
- SUBOXONE (BUPRENORPHINE/NALOXONE) AS AN AGONIST OPIOID TREATMENT IN SPAIN: A BUDGETARY IMPACT ANALYSIS
- LOWERING THE THRESHOLD. MODELS OF ACCESIBLE METHADONE AND BUPRENORPHINE TREATMENT
- WHEN A NEW DRUG PROMOTES THE INTEGRATION OF TREATMENT MODALITIES: SUBOXONE AND HARM REDUCTION
- FINNISH EXPERIENCE WITH BUPRENORPHINE-NALOXONE COMBINATION (SUBOXONE): SURVEY EVALUATIONS WITH INTRAVENOUS DRUG USERS
- AN OPEN TRIAL OF LOW DOSE BUPRENORPHINE IN TREATING METHADONE WITHDRAWAL